Clonazepam

Clonazepam

SCHEMBL38899

O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of Clonazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 known ✓ P14867 5/20 1.00
GABRA5 known ✓ P31644 5/20 1.00
GABRA3 known ✓ P34903 5/20 1.00
GABRA2 known ✓ P47869 5/20 1.00
GABRB2 known ✓ P47870 4/20 1.00
GABRG2 known ✓ P18507 4/20 1.00
GABRB3 known ✓ P28472 4/20 1.00
GABRP known ✓ O00591 3/20 1.00
GABRD known ✓ O14764 3/20 1.00
GABRB1 known ✓ P18505 3/20 1.00
GABRA4 known ✓ P48169 3/20 1.00
GABRE known ✓ P78334 3/20 1.00
GABRA6 known ✓ Q16445 3/20 1.00
GABRG1 known ✓ Q8N1C3 3/20 1.00
GABRG3 known ✓ Q99928 3/20 1.00
GABRQ known ✓ Q9UN88 3/20 1.00
ADRA1A P35348 1/20 1.00
LMNA P02545 2/20 0.73
PDE4D Q08499 2/20 0.73
HPGD P15428 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clonazepam SCHEMBL13747803 1.00 GABRA1 (1.00) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL29743048 1.00 GABRA1 (1.00) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL5501860 1.00 GABRA1 (1.00) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL13746712 1.00 GABRA1 (1.00) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL29369721 1.00 GABRA1 (1.00) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL29361251 1.00 GABRA1 (1.00) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL9834407 0.99 GABRA1 (0.98) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL31321724 0.99 GABRA1 (0.98) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL28390843 0.99 GABRA1 (0.98) GABRA1GABRA5GABRA3GABRA2GABRB2
Clonazepam SCHEMBL20771795 0.98 GABRA1 (0.96) GABRA1GABRA5GABRA3GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 36036 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747280-A2 METHODS FOR TREATING MULTIPLE MYELOMA Janssen Biotech, Inc. (US) 2026-05-27 EP claimed
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
CN-118387863-B Preparation method and application of graphene/carbon nanotube composite slurry Anhui University of Science and Technology (CN) 2026-05-26 CN claimed
CN-122072257-A Method for rapidly detecting poison in blood 中国科学院大连化学物理研究所 2026-05-22 CN claimed
US-20260137654-A1 COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER THE REGENTS OF THE UNIV OF CALIFORNIA (US) 2026-05-21 US claimed
US-12624036-B2 Method of treating post-traumatic stress disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
US-12624037-B2 Method of treating agitation, aggressive behavior, and impulse control disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
US-20260124211-A1 COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) 2026-05-07 US claimed
EP-4736841-A1 A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT IQ medical GmbH (DE) 2026-05-06 EP claimed
US-12616680-B2 Combined use of biotin and thiamine in the treatment of huntington's disease CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2026-05-05 US claimed
EP-0240904-A2 Process for the preparation of solid pharmaceutical forms BASF Aktiengesellschaft (DE) 1987-10-14 EP claimed
EP-0098113-B1 A COMBINATION OF BETA-ADRENOCEPTOR ANTAGONISTS AND ANXIOLYTIC AGENTS AYERST, MCKENNA AND HARRISON INC. (CA) 1986-09-03 EP claimed
EP-0169618-A2 Method for making uniformly sized particles from water-insoluble organic compounds STERILIZATION TECHNICAL SERVICES, Inc. (US) 1986-01-29 EP claimed
US-4557934-A ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE THE PROCTER & GAMBLE COMPANY (US) 1985-12-10 US claimed
EP-0098113-A1 A combination of beta-adrenoceptor antagonists and anxiolytic agents AYERST, MCKENNA AND HARRISON INC. (CA) 1984-01-11 EP claimed
US-4316897-A TRANQUILIZERS HOFFMANN-LA ROCHE INC. (US) 1982-02-23 US claimed
EP-0025546-A2 Therapeutical use of tranquillizing benzodiazepine derivatives and mixtures containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-03-25 EP claimed
EP-0022771-A4 RADIO RECEPTOR ASSAY FOR BENZODIAZEPINES IN PLASMA AND OTHER BIOLOGICAL SPECIMENS. US HEALTH (US) 1981-02-04 EP claimed
EP-0022771-A1 RADIO RECEPTOR ASSAY FOR BENZODIAZEPINES IN PLASMA AND OTHER BIOLOGICAL SPECIMENS THE UNITED STATES OF AMERICA, represented by DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1981-01-28 EP claimed
WO-1980000750-A1 RADIO RECEPTOR ASSAY FOR BENZODIZAPINES IN PLASMA AND OTHER BIOLOGICAL SPECIMENS US COMMERCE (US) 1980-04-17 WO claimed